Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Executives Buy Around $15M Of 4 Stocks

Published 06/04/2022, 12:02
Updated 06/04/2022, 12:40
© Reuters.  Executives Buy Around $15M Of 4 Stocks

Although U.S. stocks closed sharply lower on Tuesday, there were a few notable insider trades.

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

JELD-WEN Holding

  • The Trade: JELD-WEN Holding, Inc. (NYSE: JELD) 10% owner Turtle Creek Asset Management Inc acquired a total of 356,317 shares at an average price of $20.30. To acquire these shares, it cost around $7.23 million.
  • What’s Happening: Credit Suisse (SIX:CSGN) initiated coverage on JELD-WEN Holding with an Outperform rating and announced a price target of $24.
  • What JELD-WEN Holding Does: JELD-WEN Holding Inc is engaged in door and window manufacturing. The company design, produce and distribute interior and exterior doors, windows, and related products.
Cullinan Oncology
  • The Trade: Cullinan Oncology, Inc. (NASDAQ: CGEM) 10% owner Mark Lampert acquired a total of 276,000 shares at an average price of $10.75. To acquire these shares, it cost around $2.97 million.
  • What’s Happening: Cullinan Oncology recently announced clinical and regulatory updates from Phase 1/2a trial of CLN-081 in a non-small cell lung cancer (NSCLC) setting.
  • What Cullinan Oncology Does: Cullinan Oncology Inc is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients.
Don’t forget to check out our premarket coverage here .

Also check this: Expedia And 3 Other Stocks Insiders Are Selling

Sensient Technologies

  • The Trade: Sensient Technologies Corporation (NYSE: SXT) 10% owner Freemont Capital Pte Ltd bought a total of 33,238 shares at an average price of $84.96. To acquire these shares, it cost around $2.82 million.
  • What’s Happening: The company’s stock dropped around 7% over the past six months.
  • What Sensient Technologies Does: Sensient Technologies manufactures and markets natural and synthetic colors, flavors, and flavor extracts. The company has a widespread network of facilities around the globe, and its customers operate across a variety of end markets.
FIGS
  • The Trade: FIGS, Inc. (NYSE: FIGS) 10% owner Thomas Tull bought a total of 79,150 shares at an average price of $22.05. The insider spent around $1.75 million to buy those shares.
  • What’s Happening: FIGS, last month, reported better-than-expected Q4 EPS and sales results.
  • What FIGS Does: FIGS Inc is a healthcare apparel company. It offers more fitted scrubs for men and women made of its proprietary fabric FIONx, which provides four-way stretch and has anti-odor, anti-wrinkle and moisture-wicking properties.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read at Benzinga

Read the original article on Benzinga

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.